Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China

BACKGROUND: According to the Chinese guidelines for lipid management (2023), evolocumab in combination with statins was recommended as secondary prevention of cardiovascular disease. However, because of the variation in the price of evolocumab and its different methods of confirming clinical efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Yuansheng, Liu, Jinyu, Zhan, Xiaolian, Zhang, Yu, You, Ruxu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690971/
https://www.ncbi.nlm.nih.gov/pubmed/38041072
http://dx.doi.org/10.1186/s12962-023-00501-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690971/
https://www.ncbi.nlm.nih.gov/pubmed/38041072
http://dx.doi.org/10.1186/s12962-023-00501-4

Ejemplares similares